Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Income towards Parent Company: 2015-2024

Historic Income towards Parent Company for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to -$237.1 million.

  • Editas Medicine's Income towards Parent Company rose 59.58% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 56.38% down from last year.
  • Latest data reveals that Editas Medicine reported Income towards Parent Company of -$237.1 million as of FY2024, which was down 56.38% from -$151.6 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's Income towards Parent Company registered a high of -$132.2 million during FY2020, and its lowest value of -$237.1 million during FY2024.
  • In the last 3 years, Editas Medicine's Income towards Parent Company had a median value of -$220.4 million in 2022 and averaged -$203.0 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first soared by 31.22% in 2023, then slumped by 56.38% in 2024.
  • Editas Medicine's Income towards Parent Company (Yearly) stood at -$132.2 million in 2020, then crashed by 45.60% to -$192.5 million in 2021, then declined by 14.49% to -$220.4 million in 2022, then surged by 31.22% to -$151.6 million in 2023, then crashed by 56.38% to -$237.1 million in 2024.